Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Egfr Nsclc'

Egfr Nsclc published presentations and documents on DocSlides.

Optimal treatment for elderly patients with NSCLC

Optimal treatment for elderly patients with NSCLC

  • cheryl-pisano
  • 43 Slides

Giorgio V. Scagliotti. University. of . Torino,....

No Does the New EPOC trial eliminate anti-EGFR antibodies a

No Does the New EPOC trial eliminate anti-EGFR antibodies a

  • sherrill-nordquist
  • 22 Slides

The New EPOC Study. Randomi. ze. Surgery. Oxalipl...

Audit of EGFR mutation testing in patients with proven Non-

Audit of EGFR mutation testing in patients with proven Non-

  • aaron
  • 31 Slides

On behalf of the North of England Cancer Network ...

LIFE Study: Lower Systolic Pressure Slowed Progression of R

LIFE Study: Lower Systolic Pressure Slowed Progression of R

  • phoebe-click
  • 7 Slides

in . Hypertension. From ESH 2016 | POS 4C:. Sverr...

L’algoritmo terapeutico

L’algoritmo terapeutico

  • calandra-battersby
  • 26 Slides

attraverso . i . c. asi clinici. Giuseppe . Valma...

Estimated costs of managing treatment-related adverse

Estimated costs of managing treatment-related adverse

  • lindy-dunigan
  • 8 Slides

eventsof. . nivolumab. and . docetaxel. in the...

James Yang,

James Yang,

  • pasty-toler
  • 93 Slides

MD. The Evolving Treatment Landscape in NSCLC: Co...

Best Practices in Nursing Management of EGFR Inhibitor Rash

Best Practices in Nursing Management of EGFR Inhibitor Rash

  • olivia-moreira
  • 58 Slides

Beth . Eaby. -Sandy, MSN, CRNP, OCN. ®. Nurse Pr...

Defining Epidermal Growth Factor Receptor exon 20 mutant se

Defining Epidermal Growth Factor Receptor exon 20 mutant se

  • danika-pritchard
  • 16 Slides

k. inase . i. nhibition. Danny Rayes . Epidermal ...

Defining Epidermal Growth Factor Receptor exon 20 mutant se

Defining Epidermal Growth Factor Receptor exon 20 mutant se

  • trish-goza
  • 14 Slides

k. inase . i. nhibition. Danny Rayes . Lung Cance...

Switch to DRV/r + RAL

Switch to DRV/r + RAL

  • debby-jeon
  • 5 Slides

SPARE . Study. SPARE Study: switch to DRV/r + RAL...

Molecular Subtypes:

Molecular Subtypes:

  • giovanna-bartolotta
  • 29 Slides

Not Quite Ready . for Prime Time. Scott Kopetz, M...

Comparision

Comparision

  • jane-oiler
  • 33 Slides

of the expression of . 17-beta-hydroxysteroid . ...

The Epidermal Growth Factor Receptor Regulates

The Epidermal Growth Factor Receptor Regulates

  • debby-jeon
  • 40 Slides

Cofilin. Activity and Promotes Transmissible Gas...

Where we are with targeted

Where we are with targeted

  • stefany-barnette
  • 32 Slides

therapies . for . cholangiocarcinoma. Professor J...

Canadian Diabete

Canadian Diabete

  • trish-goza
  • 13 Slides

s Association Clinical Practice Guidelines. Treat...

Antiangiogenic Agents in Advanced NSCLC

Antiangiogenic Agents in Advanced NSCLC

  • ellena-manuel
  • 0 Slides

Jared Weiss, MD . Assistant . Professor of Medici...

Chris Dobson Renal disease: AKI vs CKD

Chris Dobson Renal disease: AKI vs CKD

  • kittie-lecroy
  • 0 Slides

What is acute kidney injury (AKI). Hyperkalaemia....

The direct oral anticoagulants (DOACs)

The direct oral anticoagulants (DOACs)

  • faustina-dinatale
  • 0 Slides

and major trauma. Dr. Tina . Biss. Consultant . ...

Pharmacologic Approaches to Treating CKD in Type 2 DM (1)

Pharmacologic Approaches to Treating CKD in Type 2 DM (1)

  • calandra-battersby
  • 0 Slides

Metformin must be considered the cornerstone of t...

Figure 1.1 Distribution of NHANES participants with diabetes, self-reported cardiovascular diseas

Figure 1.1 Distribution of NHANES participants with diabetes, self-reported cardiovascular diseas

  • trish-goza
  • 0 Slides

Vol 1, CKD, Ch 1. 2. Data Source: National Health...

Systolic Blood Pressure Intervention Trial (SPRINT)

Systolic Blood Pressure Intervention Trial (SPRINT)

  • lois-ondreau
  • 0 Slides

Principal Results. Paul K. Whelton, MB, MD, MSc. ...

Renal Replacement Therapy: What the PCP Needs to Know

Renal Replacement Therapy: What the PCP Needs to Know

  • tatiana-dople
  • 0 Slides

Learning Objectives. Describe treatment options f...

EGFR-Mutated Advanced NSCLC

EGFR-Mutated Advanced NSCLC

  • sherrill-nordquist
  • 0 Slides

The Coming Paradigm Shift. Faculty. Suresh S. Ram...

Clinical Management Module

Clinical Management Module

  • stefany-barnette
  • 0 Slides

4. . (b) . Risks and Side Effects. Overview. Res...

Analytical Team Faye Cleary

Analytical Team Faye Cleary

  • phoebe-click
  • 0 Slides

Lois Kim. Dr Sally Hull. Dr . Ben Caplin. Profess...

High Impact Publication

High Impact Publication

  • yoshiko-marsland
  • 0 Slides

. Steven B. Maron. , Lindsay Alpert, . Heewon. ...

1/2015 Samuel Lai Contrast Nephropathies

1/2015 Samuel Lai Contrast Nephropathies

  • celsa-spraggs
  • 0 Slides

Understand the interaction between iodine, gadoli...

NCI-Molecular Analysis for Therapy Choice

NCI-Molecular Analysis for Therapy Choice

  • phoebe-click
  • 0 Slides

(NCI-MATCH or EAY131). Interim Analysis Results....

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

  • pasty-toler
  • 0 Slides

This program will include a discussion of off-lab...

Chronic Kidney Disease The Basics

Chronic Kidney Disease The Basics

  • stefany-barnette
  • 0 Slides

Kevin Harley, M.D.. Assistant Clinical Professor....

Raising the Bar in the Management of Advanced/Metastatic NSCLC

Raising the Bar in the Management of Advanced/Metastatic NSCLC

  • debby-jeon
  • 0 Slides

Dr Tan . Jiunn. Liang. Clinical Specialist (Resp...

Systolic Blood Pressure Intervention Trial (SPRINT)

Systolic Blood Pressure Intervention Trial (SPRINT)

  • pamella-moone
  • 0 Slides

Principal Results. Paul K. Whelton, MB, MD, MSc. ...

2 Vol 1, CKD, Ch 1 vol

2 Vol 1, CKD, Ch 1 vol

  • liane-varnes
  • 0 Slides

1 Table 1.1 Distribution of NHANES participants...

Data Source: National Health and Nutrition Examination Survey (NHANES), 1999-2002, 2003-2006, 2007

Data Source: National Health and Nutrition Examination Survey (NHANES), 1999-2002, 2003-2006, 2007

  • kittie-lecroy
  • 0 Slides

.. . 2016 Annual Data Report, Vol 1, CKD, . Ch....

Challenges in RAS Wild-Type mCRC

Challenges in RAS Wild-Type mCRC

  • marina-yarberry
  • 0 Slides

Introduction. Decision-Making Algorithm for First...

A Primary Care Approach to CKD Management

A Primary Care Approach to CKD Management

  • myesha-ticknor
  • 0 Slides

Learning Objectives. Facilitate timely testing an...

A PCP’s Guide to CKD Screening and Delaying Progression

A PCP’s Guide to CKD Screening and Delaying Progression

  • luanne-stotts
  • 0 Slides

Learning Objectives. Utilize appropriate screenin...

Tenofovir nephrotoxicity in resource limited setting of Western India : Higher rate of renal functi

Tenofovir nephrotoxicity in resource limited setting of Western India : Higher rate of renal functi

  • conchita-marotz
  • 0 Slides

A.Dravid. 1. ,A.Sadre. 2. ,S.Dhande. 1. , A.Borka...

Murali Nagarajan 1 , Ramya

Murali Nagarajan 1 , Ramya

  • aaron
  • 0 Slides

Gaddikeri. 1. , . Kedar. Sharbidre. 1. , . Mira...

Copyright © 2024 DocSlides. All Rights Reserved